Huakang Biomedical Holdings Co (HKSE:08622) Equity-to-Asset : 0.78 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Huakang Biomedical Holdings Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$55.80 Mil. Huakang Biomedical Holdings Co's Total Assets for the quarter that ended in Dec. 2023 was HK$71.44 Mil. Therefore, Huakang Biomedical Holdings Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.78.

The historical rank and industry rank for Huakang Biomedical Holdings Co's Equity-to-Asset or its related term are showing as below:

HKSE:08622' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57 Med: 0.85 Max: 0.9
Current: 0.78

During the past 9 years, the highest Equity to Asset Ratio of Huakang Biomedical Holdings Co was 0.90. The lowest was 0.57. And the median was 0.85.

HKSE:08622's Equity-to-Asset is ranked better than
79.16% of 1089 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs HKSE:08622: 0.78

Huakang Biomedical Holdings Co Equity-to-Asset Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Equity-to-Asset Chart

Huakang Biomedical Holdings Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.90

0.85

0.86

0.85

0.78

Huakang Biomedical Holdings Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.85	-	0.85	-	0.78

Competitive Comparison of Huakang Biomedical Holdings Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Huakang Biomedical Holdings Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Huakang Biomedical Holdings Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huakang Biomedical Holdings Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Huakang Biomedical Holdings Co's Equity-to-Asset falls into.

Huakang Biomedical Holdings Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Huakang Biomedical Holdings Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	55.804	/	71.44
	=	0.78

Huakang Biomedical Holdings Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	55.804	/	71.44
	=	0.78

Huakang Biomedical Holdings Co (HKSE:08622) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Huakang Biomedical Holdings Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Huakang Biomedical Holdings Co (HKSE:08622) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN

Website

http://www.szhuakang.com

Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.

Executives

Tgga, Llc	2106 Person having a security interest in shares
Lau Lai Yee	2201 Interest of corporation controlled by you
Kokusai Resources Company Limited	2101 Beneficial owner
Zhang Shuguang	2101 Beneficial owner
Crystal Grant Limited	2101 Beneficial owner
Chang Yim Yang	2401 A concert party to an agreement to buy shares
Ever Charming Inc.	2101 Beneficial owner
Wealthy Pride Investment Limited	2101 Beneficial owner

Huakang Biomedical Holdings Co (HKSE:08622) Headlines

No Headlines